Disulfiram: mechanisms, applications, and challenges

J Lanz, N Biniaz-Harris, M Kuvaldina, S Jain, K Lewis… - Antibiotics, 2023 - mdpi.com
Background: Since disulfiram's discovery in the 1940s and its FDA approval for alcohol use
disorder, other indications have been investigated. This review describes potential clinical …

Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities

EOJ Porta, K Kalesh, PG Steel - Frontiers in pharmacology, 2023 - frontiersin.org
Chagas disease is a vector-borne illness caused by the protozoan parasite Trypanosoma
cruzi (T. cruzi). It poses a significant public health burden, particularly in the poorest regions …

Combination Therapy of Curcumin and Disulfiram Synergistically Inhibits the Growth of B16-F10 Melanoma Cells by Inducing Oxidative Stress

SS Fontes, ML Nogueira, RB Dias, CAG Rocha… - Biomolecules, 2022 - mdpi.com
Oxidative stress plays a central role in the pathophysiology of melanoma. Curcumin (CUR)
is a polyphenolic phytochemical that stimulates reactive oxygen species (ROS) production …

New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi, the causative agent of Chagas disease

SMF Murta, PA Lemos Santana… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Benznidazole, the drug of choice for treating Chagas Disease (CD), has
significant limitations, such as poor cure efficacy, mainly in the chronic phase of CD …

Tackling the Challenges of human Chagas Disease: a Comprehensive Review of Treatment Strategies in the Chronic Phase and Emerging Therapeutic Approaches

LG Ramos, KR de Souza, PAS Júnior, CC Câmara… - Acta Tropica, 2024 - Elsevier
Chagas disease (CD), caused by the flagellated protozoan Trypanosoma cruzi (T. cruzi),
affects approximately 7 million people worldwide and is endemic in Latin America …

Are patents important indicators of innovation for Chagas disease treatment?

AP Caroli, FRP Mansoldo, VS Cardoso… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Chagas disease is a neglected, endemic disease in 21 countries, spreading to
non-endemic countries too. Like other neglected diseases affecting primarily low-and middle …

Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models

MNC Soeiro, PA Sales-Junior, VRA Pereira… - Memórias do Instituto …, 2024 - SciELO Brasil
Chagas disease is a tropical neglected disease that affects millions of people worldwide, still
demanding a more effective and safer therapy, especially in its chronic phase which lacks a …

What are the translational challenges associated with Chagas disease drug discovery?

I Ramírez-Macías, P García-Huertas… - Expert Opinion on Drug …, 2024 - Taylor & Francis
Chagas disease is endemic in Latin American countries. However, cases have been found
in non-endemic areas such as the United States, Canada, Japan and some countries in …

A Promising Amphotericin B Derivative Induces Morphological Alterations, Mitochondrial Damage, and Oxidative Stress In Vitro and Prevents Mice from Death …

I Martínez, L Rivera-Santiago… - Microorganisms, 2024 - mdpi.com
Chagas Disease is a neglected tropical disease caused by the protozoan parasite
Trypanosoma cruzi, affecting 6–8 million people, mainly in Latin America. The medical …

[HTML][HTML] In vitro and in vivo evaluation of diethyldithiocarbamate with copper ions and its liposomal formulation for the treatment of Staphylococcus aureus and …

L Kaul, AI Abdo, T Coenye, S Swift, A Zannettino… - Biofilm, 2023 - Elsevier
Surgical site infections (SSIs) are mainly caused by Staphylococcus aureus (S. aureus) and
Staphylococcus epidermidis (S. epidermidis) biofilms. Biofilms are aggregates of bacteria …